Immunosuppression: Towards a logical approach in liver transplantation

Clinical and Experimental Immunology

Volumn 139, Issue 1, 2005, Pages 2-10

  Perry, I ^a   Neuberger, James ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Immunosuppression; Liver; Synergy; Transplantation

Indexed keywords

2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ALEMTUZUMAB; ANTIMETABOLITE; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; FINGOLIMOD; FK 779; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LEFLUNOMIDE; MALONONITRILAMIDE; MERCAPTOPURINE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOGRAFT; ANEMIA; ARTERY THROMBOSIS; BONE MARROW SUPPRESSION; BRONCHOSPASM; CATARACT; CLINICAL MEDICINE; CLINICAL TRIAL; COMORBIDITY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG USE; DYSLIPIDEMIA; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GOUT; GRAFT REJECTION; GRAFT SURVIVAL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MOUTH ULCER; MYOSITIS; NAUSEA; NEOPLASM; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PERIPHERAL EDEMA; PERSONALITY DISORDER; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEIZURE; SEPSIS; SERUM SICKNESS; TERATOGENICITY; THROMBOCYTOPENIA; TREMOR; VEIN THROMBOSIS; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

ADRENAL CORTEX HORMONES; ALGORITHMS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CALCINEURIN; CARDIOVASCULAR DISEASES; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; SIROLIMUS;

EID: 11244253101     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02662.x     Document Type: Review

References (64)

1. Vilatoba M, Contreras JL, Eckhoff DE. New immunosuppressive strategies in liver transplantation: balancing efficacy and toxicity. Current Opin Organ Transplant 2003; 8:139-45.
2. Sherlock S, Dooley J. Diseases of the liver and biliary system, 11th edn. Oxford: Blackwell Science Ltd, 2002.
3. Wiesner RH, Demetris AJ, Belle SH et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28:45.
4. Neuberger J, Adams DH. What is the significance of acute liver allograft rejection? J Hepatol 1998; 29:143-50.
5. Lowes JR, Hubscher SG, Neuberger JM. Chronic rejection of the liver allograft. Gastroenterol Clin North Am 1993; 22:401-20.
6. Pfeilschifter J, Muhl H. Immunopharmacology: anti-inflammatory therapy targeting transcription factors. Eur J Pharmacol 1999; 375:237-45.
7. Mueller XM. Drug immunosuppression therapy for adult heart transplantation. Part 1. Immune response to allograft and mechanism of action of immunosuppressants. Ann Thorac Surg 2004; 77:354-62.
8. Jiang H, Kobayashi M. Differences between cyclosporin A and tacrolimus in organ transplantation. Transplant Proc 1999; 31:1978-80.
9. Sterneck M, Zadeh KM, Groteluschen R, Broring D, Rogiers X, Fischer L. Clinical use of C2 monitoring in long-term liver transplant recipients. Transplant Proc 2002; 34:3304-6.
10. Levy G, Villamil F, Samuel D, et al. for the LIS2T Study Group. Results of list, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with CO monitoring in de novo liver transplantation. Transplantation 2004; 77:1632-8.
11. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-40.
12. Kahan BD. The limitations of calcineurin and mTOR inhibitors: new directions for immunosuppressive strategies. Transplant Proc 2002; 34:130-3.
13. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331:1110-5.
14. Nakagawa M, Sakamoto N, Enomoto N et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004; 313:42-7.
15. Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15:1699-708.
16. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34:1081-5.
17. Armstrong VW, Shipkova M, von Ahsen N, Oellerich M. Analytic aspects of monitoring therapy with thiopurine medications. Ther Drug Monit 2004; 26:220-6.
18. Moreno JM, Rubio E, Pons F et al. Usefulness of mycophenolate mofetil in patients with chronic renal insufficiency after liver transplantation. Transplant Proc 2003; 35:715-7.
19. Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc 2003; 35:209S-216S.
20. Trotter JF. Sirolimus in liver transplantation. Transplant Proc 2003; 35:S193-200.
21. Groth CG, Backman L, Morales JM et al. Sirolimus (rapamycin)- based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:1036-42.
22. Koehl GE, Andrassy J, Guba M et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77:1319-26.
23. Tan HP, Basu A, Shapiro R. Everolimus: an update. Current Opin Organ Transplant 2003; 8:323-6.
24. Go MR, Bumgardner GL. OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient. Transplantation 2002; 73:1957-9.
25. Vincenti F. The role of newer monoclonal antibodies in renal transplantation. Transplant Proc 2001; 33:1000-1.
26. Calmus Y, Scheele JR, Gonzalez-Pinto I et al. Immunoprophylaxis with basiliximab, a chimeric anti-leukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transplant 2002; 8:123-31.
27. Hirose R, Roberts JP, Quan D et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000; 69:307-11.
28. Tzakis AG, Tryphonopoulos P, Kato T et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77:1209-14.
29. Suzuki S. FTY720: mechanisms of action and its effect on organ transplantation. Transplant Proc 1999; 317:2779-82.
30. Cheuch S-CJ, Kahan BD. Update on FTY720: review of mechanisms and clinical results. Curr Opin Organ Transplant 2003; 8:288-98.
31. Tamura A, Li XK, Funeshima N et al. Immunosuppressive therapy using FTY720 combined with tacrolimus in rat liver transplantation. Surgery 2000; 127:47-54.
32. Sanna MG, Liao J, Jo E et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279:13839-48.
33. Schuurman HJ, Menninger K, Audet M et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. Transplantation 2002; 74:951-60.
34. Koch MJ, Brennan DC. Leflunomide: is there a place for its use in transplantation? Current Opin Organ Transplant 2003; 8:317-22.
35. Hardinger KL, Wang CD, Schnitzler MA. Prospective, pilot, open-label, short term study of conversion to leflunomide reverses chronic renal allograft dysfunction. Am J Transplant 2002; 2:867-71.
36. Williams JW, Mital D, Chong A et al. Experiences with leflunomide in solid organ transplantation. Transplantation 2002; 73: 358-66.
37. Bilolo KK, Ouyang J, Wang X et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. Transplantation 2003; 75:1881-7.
38. Deuse T, Schrepfer S, Reichenspurner H. The interaction between FK778 and tacrolimus in the prevention of rat cardiac allograft rejection is dose dependent. Transplantation 2004; 77:509-13.
39. Neuhaus P, Langrehr JM, Williams R, Calne RY, Pichlmayr R, McMaster P. Tacrolimus-based immunosuppression after liver transplantation: a randomised study comparing dual versus triple low-dose oral regimens. Transplant Int 1997; 10:253-61.
40. Ekberg H. Tailoring minimal immunosuppression long term. Transplant Proc 2003; 35:755-7.
41. Serrano J, Gonzale M, Gomez M et al. Tacrolimus is effective in both dual and triple regimens after transplantation. Transplant Proc 2002; 34:1529-30.
42. Fisher RA, Ham JM, Marcos A et al. A prospective randomised trial of mycophenalate mofetil with Neoral or tacrolimus after orthoptic liver transplantation. Transplantation 1998; 66:1616-21.
43. Wiesner R, Rabkin J, Klintmalm G et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transplant 2001; 7:442-50.
44. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001; 357:609-10.
45. Oberbauer R, Kreis H, Johnson RWG et al. Long term improvement in renal function with sirolimus after early cyclosporine withdrwal in renal transplant recipients: 2 year results of the Rapamune maintenance regimen study. Transplantation 2003; 76:364-70.
46. Flechner S, Goldfarb D, Modlin C et al. Kindey transplantation without calcinueurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74:1070-6.
47. Basu A, Tan HP, Shapiro R. Sirolimus. Curr Opin Organ Transplant 2003; 8:299-304.
48. Weisner RH for the Rapamune Liver Transplant Study Group. The safety and efficacy of sirolimus and low-dose tacrolimus versus tacrolimus in de-novo orthoptic liver transplant recipients. Results from a pilot study [Abstract]. Hepatology 2002; 36:208A.
49. Heffron TG, Smallwood GA, Davis L. Sirolimus-based immunosuppressive protocol for calcineurine sparing in liver transplantation. Transplant Proc 2002; 34:1522-3.
50. Volpin R, Angeli P, Galioto A et al. Comparison between two high dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant patients: a controlled clinical trial. Liver Transplant 2002; 8:527-34.
51. Helderman JH, Bennett WM, Cibrik DM, Kaufman DB, Klein A, Takemoto SK. Immunosuppression: practice and trends. Am J Transplant 2003; 3(Suppl. 4):41-52.
52. Heffron TG, Smallwood GA, Pillen T et al. Liver transplant induction trial of daclizumab to spare calcineurin inhibition. Transplant Proc 2002; 34:1514-5.
53. Padbury RT, Gunson BK, Dousset B et al. Long-term immunosuppression after liver transplantation: are steroids necessary? Transplant Int 1992; 5(Suppl. 1):S470-2.
54. Kim DY, Stegall MD. Steroid-sparing regimens in organ transplantation. Current Opin Organ Transplant 2001; 6:313-19.
55. Ringe B, Braun F, Schutz E et al. A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation 2001; 71:508-15.
56. Trotter JF, Wachs M, Bak T et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transplant 2001; 7:343-51.
57. Gudmundsdottir H. The road toward transplantation tolerance. Transplant Proc 2003; 35:758-9.
58. Calne R. Prope tolerance: a step in the search for tolerance in the clinic. Transplant Proc 2000; 32:2058-9.
59. Neuberger J. Treatment of hepatitis C virus infection in the allograft. Liver Transplant 2003; 9:S101-8.
60. Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transplant 2004; 10:488-91.
61. Fellstrom B. Impact and management of hyperlipidemia posttransplantation. Transplantation 2000; 70:SS51-7.
62. Zachoval R, Gerbes AL, Schwandt P, Parhofer KG. Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial. J Hepatol 2001 July; 35:86-91.
63. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004; 75:101-9.
64. Raggatt LJ, Partridge NC. HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection. Drugs 2002; 62:2185-91.